Armatus Bio
A privately held, preclinical stage biotechnology company leveraging vectorized RNAi to address urgent unmet medical needs in genetically-driven neurological diseases.
The company's lead candidate for Charcot Marie Tooth Type 1A (CMT1A) has received Orphan Drug Designation and Rare Pediatric Drug Designation, and is advancing toward IND-enabling studies as of Q2 2024. The company is also developing a preclinical vectorized RNAi asset for the rare neuromuscular disease Facioscapulohumeral Muscular Dystrophy (FSHD).
Latest Armatus Bio News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze